---
layout: default
title: Linagliptin
parent: 僅模型預測 (L5)
nav_order: 81
evidence_level: L5
indication_count: 0
---

# Linagliptin
{: .fs-9 }

證據等級: **L5** | 預測適應症: **0** 個
{: .fs-6 .fw-300 }

---

## 目錄
{: .no_toc .text-delta }

1. TOC
{:toc}

---

<div id="pharmacist">

## 藥師評估報告

</div>

# Linagliptin: Type 2 Diabetes Drug — No Repurposing Candidates Identified

---

## One-Sentence Summary

Linagliptin (DB08882) is a well-established DPP-4 inhibitor originally approved for the management of Type 2 Diabetes Mellitus. However, the TxGNN model returned **no predicted new indications** for this drug in the current evidence pack. Evaluation cannot proceed to indication-level analysis until the prediction pipeline is re-run and evidence data is populated.

---

## Quick Overview

| Item | Content |
|------|---------|
| Original Indication | Type 2 Diabetes Mellitus (DPP-4 inhibitor class) |
| Predicted New Indication | None identified (predicted_indications: empty) |
| TxGNN Prediction Score | N/A |
| Evidence Level | L5 — Model prediction only; no output returned |
| Sweden/Taiwan Market Status | Not marketed (0 authorizations on record) |
| Number of Authorizations | 0 |
| Recommended Decision | **Hold** |

---

## Why is This Prediction Reasonable?

No repurposing prediction is available from the current Evidence Pack. The `predicted_indications` array is empty, which means the TxGNN model either did not produce a ranked output for Linagliptin, or the pipeline did not complete successfully for this candidate.

Mechanism of action data is also marked as a data gap. Based on class-level knowledge, Linagliptin is a selective, competitive inhibitor of dipeptidyl peptidase-4 (DPP-4), which prolongs the action of incretin hormones (GLP-1 and GIP) to stimulate glucose-dependent insulin secretion. Whether this mechanism could translate to other indications (e.g., non-alcoholic fatty liver disease, heart failure, renal protection) is a plausible hypothesis explored in published literature — but **no model-based prediction is currently available to evaluate**.

Without a prediction from TxGNN, this report cannot perform indication-level reasoning, clinical trial mapping, or literature linkage.

---

## Clinical Trial Evidence

Currently no related clinical trials registered — no predicted indication to map evidence against.

---

## Literature Evidence

Currently no related literature available — no predicted indication to anchor a literature review.

---

## Sweden Market Information

No authorizations on record in the current dataset. The query against TFDA (query ID: 1) returned 0 results, and no license records are present in `taiwan_regulatory.licenses`.

> **Note:** Linagliptin is commercially available in multiple markets under brand names such as Tradjenta (Boehringer Ingelheim / Eli Lilly). The absence of records here may reflect a data gap in the current pipeline run rather than a genuine market absence. Cross-verification with MPA (Swedish Medical Products Agency) and TFDA databases is recommended.

---

## Safety Considerations

Please refer to the package insert for safety information.

> All safety fields (key warnings, contraindications, drug interactions) returned as data gaps or empty in this evidence pack. The DDI query returned `not_found` with 0 interactions recorded.

---

## Conclusion and Next Steps

**Decision: Hold**

**Rationale:**
The TxGNN prediction pipeline returned no candidate indications for Linagliptin, making it impossible to evaluate repurposing feasibility. No scoring, evidence triangulation, or safety mapping can be completed at this stage.

**To proceed, the following is needed:**

- **Re-run TxGNN prediction pipeline** for DB08882 and verify that `predicted_indications` is populated with at least one scored candidate
- **Retrieve MOA data** from DrugBank API (data gap DG002) to enable mechanism-to-indication reasoning
- **Retrieve TFDA package insert warnings and contraindications** (data gap DG001, currently blocking S1 safety screening)
- **Verify market status** against MPA (Sweden) and TFDA (Taiwan) directly — the current record of 0 authorizations is inconsistent with known global availability
- **Re-run DDI query** using an alternative source (e.g., DrugBank interactions endpoint or Drugs@FDA) since the current query returned `not_found`
---

